Aspirante a AMRN o ser BO de esta
La compre a 0.94 vendi a 1.25 pero Lola , Lo lamento , siguio hasta 2.95. , reboto ayer en el 61% de RFibo.
Bullisg en mensual y semanal
Recomiendo hacer DD ,
Home-Run Hitters, At Bat With Acasti Pharma
ACST’s drug, CaPre, promises to be the best-in-class Omega 3 play, used to lower triglycerides. It was recently trading at $1.01/share, with a market cap of $79M.
The biggest competitor to CaPre is Amarin's drug Vascepa. After September 2018 study results, AMRN increased from $3/share to $19.01/share recently, or a market cap of $6.29B.
The triglyceride-lowering market is large, but CaPre also potentially improves cholesterol, unlike any other Omega 3 play. If this is confirmed, CaPre becomes a game-changer.
Two of the biggest investors in ACST are arguably two of the smartest investors in biotech: Joe Edelman of Perceptive and the legendary George Haywood. Both have been accumulating.
If positive Phase III Trial results are a 30% probability (and it would appear that it's significantly higher), then the price should be $8.29/share (leading into December 2019).